The Wright classification [21] described an algorithm that classified the patients into 7 genetic subtypes (MCD, N1, A53, BN2, ST2, EZB, MYC+, and MYC–) that aided to develop a rationally targeted therapy of DLBCL on Bruton tyrosine kinase (BTK), phosphoinositide 3-kinase (PI3K), BCL2, Janus kinase (JAK), IRF4, and EZH2 molecules. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.